Literature DB >> 26990619

Genetic Association Between IL-21 Polymorphisms and Cryptorchidism in a Chinese Han Population.

Danyan Zhang1,2, Mingfu Ma2, Yan Pu3, Lianbing Li2, Gang Cao4, Yun Bai1, Bin Zhou3.   

Abstract

AIMS: Increasing evidence suggests an association between interleukin gene polymorphisms and cryptorchidism. To investigate the relationship between IL-21 gene polymorphisms and cryptorchidism susceptibility, a comprehensive genetic association study in a Chinese Han population was conducted. METHODS AND
RESULTS: A total of 328 men were enrolled in a case-control study (116 cases and 212 healthy controls). Three SNPs (rs907715, rs2055979, and rs12508721) of the IL-21 gene were genotyped using the TaqMan(®) genotyping assay. For the rs2055979 C>A polymorphism, A allele carriers had significantly decreased cryptorchidism susceptibility (p = 0.021, odds ratios [OR] = 0.58, 95% confidence intervals [CI] = 0.37-0.93) in a dominant model (AA+CA vs. CC), a codominant model (AC vs. CC; p = 0.029, OR = 0.52, 95% CI = 0.31-0.85), and an overdominant model (AC vs. CC/AA; p = 0.0087, OR = 0.53, 95% CI = 0.33-0.86). However, no associations were identified for the rs907715 C>T and rs12508721 C>A polymorphisms. In the haplotype analyses, the C-C-T haplotype of rs907715-rs2055979-rs12508721 significantly increased the risk of cryptorchidism (p < 0.0001, OR = 5.251, 95% CI = 2.528-10.906).
CONCLUSIONS: The rs2055979 C>A polymorphism of the IL-21 gene is associated with cryptorchidism susceptibility, and the C allele increases the risk of cryptorchidism in a Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26990619     DOI: 10.1089/gtmb.2015.0237

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  1 in total

1.  Association of Interleukin-31 gene polymorphisms with risk of cryptorchidism in a Chinese population.

Authors:  Bing Zou; Zhihai Yu; Jing Huang; Chunlin Tan; Haiyun Wang; Jian Fu; Xin Li; Xiaojun Wang; Shu Cui; Tielong Tang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.